ITGB3: IHC Expression in Cancer and Radioligand Target Profile
ITGB3, integrin subunit beta 3, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, ITGB3 staining is highest in kidney cancer (75% of samples positive), liver cancer (75% of samples positive) and endometrial cancer (17% of samples positive). Clinical status: FDA-approved drug (any modality).
Is ITGB3 the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.
Analyze ITGB3 freeIs ITGB3 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in kidney cancer, 75% of samples positive.
- ❔ Internalization: Not yet assessed.
- ✅ Clinical precedent: FDA-approved drug (any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
ITGB3 IHC staining by cancer type
Protein expression of ITGB3 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Kidney Cancer | 0.53 | High | 75% |
| Liver Cancer | 0.33 | Medium | 75% |
| Endometrial Cancer | 0.08 | Low | 17% |
| Prostate Cancer | 0.03 | Low | 10% |
| Skin Cancer | 0.03 | Low | 8% |
| Pancreatic Cancer | 0.03 | Low | 8% |
Not detected by IHC in: colorectal cancer, head and neck cancer, ovarian cancer, lymphoma, breast cancer, melanoma, thyroid cancer, bladder cancer, neuroendocrine tumors, cervical cancer, lung cancer, gastric cancer, testicular cancer, glioma.
Is ITGB3 internalized?
Nuclens has not yet extracted internalization evidence for ITGB3. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a free analysis to pull the latest literature.
ITGB3 clinical trials
FDA-approved drug (any modality). Nuclens hasn't indexed trials for ITGB3 yet. Search ClinicalTrials.gov for ITGB3 trials.
ITGB3 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See ITGB3 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
ITGB3 gene essentiality (DepMap)
CRISPR knockout effect across 1258 cancer cell lines: -0.11 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related kidney cancer radioligand targets
EGFR · c-MET (MET) · HER3 (ERBB3) · ITGAV · STEAP2 · Mesothelin (MSLN) · SSTR2 · HER2 (ERBB2)
See all radioligand therapy targets in kidney cancer.
See how ITGB3 ranks against 15,000 targets for your indication.
Analyze ITGB3 freeData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.